In a more modern vision, patients with a risk of relapse inferior to 35–40% such as those with CBF-AML and NPM1 mutated AML, are considered to have a favorable course so that alloHCT is not recommended in CR1 [3,4,11]. This evidence concerns the gene NPM1 and acute myeloid leukemia.